Vascular Biogenics Ltd. (VBLT) Surged To A 7-Month High On Study Results

Vascular Biogenics Ltd. (VBLT) announced Monday morning that its Phase 1/2 trial of VB-111, in the treatment of patients with recurrent platinum resistant ovarian cancer, demonstrated a statistically significant increase in overall survival.

from RTT - Before the Bell http://ift.tt/1TTgsvu
via IFTTT